On September 22, 2021, Knowledge Ecology International (KEI) obtained a copy of the $3.5 billion contract between the U.S. government and Pfizer to purchase 500 million doses of the Pfizer/BioNTech vaccine for international donation to low- and middle-income countries. The… Continue Reading
KEI will host a two hour virtual roundtable on march-in rights in U.S. government-funded inventions on Wednesday October 6, 2021 from 2pm to 4pm EDT. This will take place via Zoom, so if you would like to take part in… Continue Reading
The $10 billion contract between the U.S. government and Pfizer to purchase 500 million doses of the Pfizer COVID-19 vaccine contains a clause indicating that the $20 per dose price may be a floor and not a ceiling going forward.… Continue Reading
In the wake of the damage wrought by the COVID-19 pandemic, the World Health Organization’s World Health Assembly established a Working Group on Strengthening WHO Preparedness and Response to Health Emergencies (WGPR) in May 2021 with the following mandate: to… Continue Reading
On September 9, 2021, the Secretary of HHS, Xavier Becerra, pushed a 29 page report on proposals to address high drug prices. “Report To The White House Competition Council, on Comprehensive Plan for Addressing High Drug Prices. A Report in… Continue Reading
Knowledge Ecology International (KEI) filed comments on July 27, 2021 regarding the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA “lamin A” Gene” (86 FR 36563). The inventions are currently co-owned… Continue Reading
On July 27, 2021, Knowledge Ecology International (KEI) commented on the “Prospective Grant of an Exclusive Patent License: RP2 AAV-Based Gene Human Therapy for Ocular Diseases and Disorders Including XLRP” (86 FR 36565). The National Institutes of Health (NIH) intends… Continue Reading
(Update: The NIH provided the following response on July 30, 2021.) Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health’s (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: High ASS1 Expressing… Continue Reading
Recent years have seen several blockbuster treatments enter the market, many rooted in publicly funded foundational and pre-clinical research, and benefiting from government subsidies. In particular, we have conducted extensive research on Spinal Muscular Atrophy (SMA), which has regularly hit… Continue Reading
Spinal muscular atrophy (SMA) is a rare neuromuscular disorder, with an estimated incidence of between one and two cases per 10,000 births worldwide. The most severe form of the disease – SMA Type I – previously had close to 95%… Continue Reading